BioNTech Partners with CEPI for Lassa Fever Vaccine
Ticker: BNTX · Form: 6-K · Filed: May 30, 2024 · CIK: 1776985
| Field | Detail |
|---|---|
| Company | Biontech Se (BNTX) |
| Form Type | 6-K |
| Filed Date | May 30, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: partnership, vaccine-development, public-health
TL;DR
BioNTech teams up with CEPI on a new Lassa fever mRNA vaccine.
AI Summary
On May 29, 2024, BioNTech SE announced a collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI). This partnership aims to advance the development of a novel mRNA vaccine candidate for Lassa fever. The collaboration will leverage BioNTech's mRNA technology platform to accelerate the vaccine's journey through clinical trials.
Why It Matters
This partnership signifies BioNTech's commitment to addressing neglected tropical diseases and expanding its vaccine pipeline beyond COVID-19, potentially impacting global health security.
Risk Assessment
Risk Level: low — The filing is an announcement of a partnership and does not contain significant financial or operational risks.
Key Players & Entities
- BioNTech SE (company) — Registrant and partner
- Coalition for Epidemic Preparedness Innovations (CEPI) (company) — Partner in Lassa fever vaccine development
- May 29, 2024 (date) — Date of announcement
FAQ
What is the primary goal of the collaboration between BioNTech SE and CEPI?
The primary goal is to advance the development of a novel mRNA vaccine candidate for Lassa fever.
What technology will be utilized in the development of the Lassa fever vaccine?
BioNTech's mRNA technology platform will be utilized.
When was this collaboration announced?
The collaboration was announced on May 29, 2024.
What is the specific disease targeted by this new vaccine candidate?
The specific disease targeted is Lassa fever.
What is the form type filed with the SEC?
The form type filed is a Form 6-K.
Filing Stats: 257 words · 1 min read · ~1 pages · Grade level 14.6 · Accepted 2024-05-29 19:21:17
Filing Documents
- form6-kcepipr29may2024.htm (6-K) — 15KB
- ex99_120240529xcepixprxenx.htm (EX-99.1) — 33KB
- image_0.jpg (GRAPHIC) — 3KB
- image_1.jpg (GRAPHIC) — 9KB
- 0001776985-24-000047.txt ( ) — 65KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a16 OR 15d16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant's name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20F or Form 40F Form 20F Form 40F Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(1) Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(7) DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On May 29, 2024, BioNTech SE (the "Company") announced that the Company and the Coalition for Epidemic Preparedness Innovations ("CEPI") are expanding their strategic partnership to contribute to building a sustainable and resilient end-to-end African vaccine ecosystem.The press release is attached hereto as Exhibit 99.1. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By s Jens Holstein By s Dr. Sierk Poetting Name Jens Holstein Name Dr. Sierk Poetting Title Chief Financial Officer Title Chief Operating Officer Date May 29, 2024 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 BioNTech and CEPI Expand Partnership to Strengthen Africa's mRNA Vaccine Ecosystem